| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Yale Cancer Center, Yale University School of Medicine, Divisions of Medical and Surgical Oncology, 333 Cedar Street, FMP 116, New Haven, Connecticut 06520, USA
Correspondence: Address correspondence and reprint requests to: Muhammad Wasif Saif, MD, MBBS; E-mail: wasif.saif{at}yale.edu
Bevacizumab is the first U.S. Food and Drug Association-approved vascular endothelial growth factor-targeted agent that greatly increases progression-free and overall survival in combination with standard chemotherapy regimens in patients with metastatic colorectal cancer. Although bevacizumab is generally well tolerated, some serious adverse events have occurred in some patients in clinical trials, including arterial thromboembolism and gastrointestinal (GI) perforation. GI perforation was first observed in the pivotal phase 3 trial, in which six events occurred in bevacizumab group (1.5%), compared with no events in the control group. Since then, similar rates of GI perforation have been observed in other large trials. Typical presentation was abdominal pain associated with constipation and vomiting. Such events occurred throughout treatment and were not correlated with duration of exposure. No difference in rate of GI perforations was found in patients who did and did not have a baseline history of peptic ulcer disease, diverticulosis, and history of chronic use of non-steroidal anti-inflammatory drugs. However, the incidence of GI perforation seemed to be higher in patients with primary tumor intact, recent history of sigmoidoscopy or colonoscopy, or previous adjuvant radiotherapy, but it is necessary to confirm these preliminary findings by multivariate analyses. The mechanism responsible for causing GI perforation is not known and may be multifactorial. Bevacizumab should be permanently discontinued in patients who develop GI perforation. This article reviews the incidence, presentation, pathogenesis, risk factors, and management of GI perforation in patients with colorectal cancer who are treated with bevacizumab.
Key Words: Bevacizumab • Colorectal cancer • Gastrointestinal perforation
This article has been cited by other articles:
 |
|
 |
|
  K. Sakamoto, S. Maeda, Y. Hikiba, H. Nakagawa, Y. Hayakawa, W. Shibata, A. Yanai, K. Ogura, and M. Omata Constitutive NF-{kappa}B Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth Clin. Cancer Res., April 1, 2009; 15(7): 2248 - 2258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Norden, J. Drappatz, A. S. Ciampa, L. Doherty, D. C. LaFrankie, S. Kesari, and P. Y. Wen Colon perforation during antiangiogenic therapy for malignant glioma Neuro-oncol, January 1, 2009; 11(1): 92 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Estilo, M. Fornier, A. Farooki, D. Carlson, G. Bohle III, and J. M. Huryn Osteonecrosis of the Jaw Related to Bevacizumab J. Clin. Oncol., August 20, 2008; 26(24): 4037 - 4038. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cowman, J. Stebbing, and M. Tuthill Large bowel perforation associated with capecitabine treatment for breast cancer Ann. Onc., August 1, 2008; 19(8): 1510 - 1511. [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Dudar, L. D. D'Andrea, R. Di Stasi, C. Pedone, and J. L. Wallace A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner Am J Physiol Gastrointest Liver Physiol, August 1, 2008; 295(2): G374 - G381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tol, M. Koopman, C. J. Rodenburg, A. Cats, G. J. Creemers, J. G. Schrama, F. L. G. Erdkamp, A. H. Vos, L. Mol, N. F. Antonini, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity Ann. Onc., April 1, 2008; 19(4): 734 - 738. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
